Assessment of humoral immune function in chronic obstructive pulmonary disease (COPD) patients: an innovative strategy for COPD phenotyping (AiCOP)

慢性阻塞性肺疾病 (COPD) 患者体液免疫功能的评估：COPD 表型分析的创新策略 (AiCOP)

• 批准号: 486188
• 负责人: Patel Zil
• 金额: $ 1.27万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486188&lang=en
• 关键词: Acute Exacerbation Risk Ratio; Acute Exacerbations Of Copd (Aecopd); Adaptive Immunity; Chronic Obstructive Pulmonary Disease (Copd); Humoral Immunodeficiency; Immunoglobulins; Inflammation; Polysaccharide Vaccine Response; Respiratory Infections; T-Cell-

Chronic obstructive pulmonary disease (COPD) is a global health concern that was identified as the 3rd leading cause of death. A majority of COPD patients experience disease flare-ups known as recurrent exacerbations, leading to accelerated decline in lun

慢性阻塞性肺疾病（COPD）是一个全球性的健康问题，被确定为第三大死亡原因。大多数COPD患者会经历疾病发作，称为复发性加重，导致肺功能加速下降，